EXACT Therapeutics AS (DE:56F) has released an update.
EXACT Therapeutics AS, a Norwegian precision medicine firm, has been granted a UK patent for its Acoustic Cluster Therapy (ACT) in combination with immunotherapy for cancer and autoimmune diseases. The patent aligns with the company’s strategy to enhance its oncology-focused intellectual property portfolio. ACT is a unique technology designed to improve the delivery of therapeutic agents through ultrasound activation.
For further insights into DE:56F stock, check out TipRanks’ Stock Analysis page.